美股A股
StockGist
Back
8-K2026-05-14· qwen-plus

CYPH · Leap Therapeutics, Inc.

0001104659-26-060686

SEC filing

Summary

Cypherpunk Technologies reported a $77.2 million net loss for Q1 2026, driven primarily by a $77.6 million unrealized loss on its ZEC treasury as the price fell from $508.09 to $240.47, while Leap Therapeutics subsidiary advanced sirexatamab with FDA Fast Track designation and positive biomarker-stratified clinical results.

Key takeaways

Full analysis

Cypherpunk Technologies’ Q1 2026 results reflect a sharp divergence between its dual business lines: a volatile digital asset treasury strategy and a maturing oncology pipeline via Leap Therapeutics. The $77.2 million net loss was overwhelmingly driven by a $77.6 million unrealized loss on ZEC holdings — a direct consequence of ZEC’s 52.7% price decline during the quarter (from $508.09 to $240.47). This accounting impact dominates the P&L, masking underlying operational improvements: R&D spend collapsed 98.7% year-over-year to $0.2 million as clinical trial activity wound down, and G&A rose modestly to $4.7 million due to stock-based compensation. Critically, the biotech segment delivered material clinical validation: at AACR 2026, Leap presented data showing sirexatamab significantly improved ORR and OS in DKK1-high CRC patients using a newly validated plasma assay — a key step toward precision oncology commercialization. The FDA Fast Track designation in May 2026 further de-risks regulatory timing and enables rolling NDA submission. Meanwhile, Cypherpunk’s strategic pivot into privacy infrastructure — including a $5 million investment in ZODL and launch of an investor dashboard tracking ZEC metrics — signals intent to build ecosystem value beyond passive holding. However, the financial statements reveal acute sensitivity to crypto price swings: ZEC holdings constituted $73.8 million of total assets ($87.4M) as of March 31, 2026, and the company’s cash position declined to $6.7 million, raising near-term liquidity considerations absent additional financing or monetization events. No forward guidance was disclosed in the filing or Exhibit 99.1.